Payment overview · 2025
General Payments
$50.22
3 reported records · 1 companies
Healthcare provider profile · identity verified
Tomas Ferrer Capiro, M.D
Allopathic & Osteopathic Physicians|General Practice · ORLANDO, FL · NPI 1548666183
Verified facts
What the public records show
CMS Open Payments records show Tomas Ferrer Capiro, M.D received $50.22 in general payments during 2025 across 3 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.22 | 100.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $50.22 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.22 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 202 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
202 | 55 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
25 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 868 | 302 |
| Amlodipine Besylate | Amlodipine Besylate | 671 | 224 |
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 193 |
| Metformin Hcl | Metformin Hcl | 481 | 175 |
| Ezetimibe | Ezetimibe | 455 | 164 |
| Gabapentin | Gabapentin | 449 | 154 |
| Omeprazole | Omeprazole | 417 | 145 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 393 | 135 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 125 |
| Lisinopril | Lisinopril | 365 | 119 |
| Alendronate Sodium | Alendronate Sodium | 364 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 114 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 352 | 118 |
| Losartan Potassium | Losartan Potassium | 326 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 106 |
| Tizanidine Hcl | Tizanidine Hcl | 259 | 92 |
| Fluticasone Propionate | Fluticasone Propionate | 250 | 88 |
| Trazodone Hcl | Trazodone Hcl | 241 | 83 |
| Furosemide | Furosemide | 234 | 86 |
| Carvedilol | Carvedilol | 226 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 85 |
| Ozempic | Semaglutide | 214 | 40 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 210 | 82 |
| Farxiga | Dapagliflozin Propanediol | 202 | 55 |
| Telmisartan | Telmisartan | 191 | 64 |
| Meloxicam | Meloxicam | 176 | 70 |
| Montelukast Sodium | Montelukast Sodium | 176 | 65 |
| Nitroglycerin | Nitroglycerin | 176 | 62 |
| Jardiance | Empagliflozin | 162 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 57 |
| Finasteride | Finasteride | 129 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 40 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 123 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 43 |
| Memantine Hcl | Memantine Hcl | 113 | 45 |
| Buspirone Hcl | Buspirone Hcl | 111 | 40 |
| Simvastatin | Simvastatin | 111 | 41 |
| Glipizide | Glipizide | 108 | 40 |
| Sertraline Hcl | Sertraline Hcl | 108 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 41 |
| Prednisone | Prednisone | 102 | 44 |
| Irbesartan | Irbesartan | 101 | 38 |
| Enalapril Maleate | Enalapril Maleate | 97 | 36 |
| Azelastine Hcl | Azelastine Hcl | 96 | 39 |
| Eliquis | Apixaban | 95 | 33 |
| Tramadol Hcl | Tramadol Hcl | 90 | 26 |
| Betamethasone Valerate | Betamethasone Valerate | 86 | 38 |
| Donepezil Hcl | Donepezil Hcl | 86 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 85 | 31 |
| Azithromycin | Azithromycin | 83 | 69 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 32 |
| Pregabalin | Pregabalin | 76 | 19 |
| Famotidine | Famotidine | 73 | 36 |
| Ketoconazole | Ketoconazole | 73 | 25 |
| Clonazepam | Clonazepam | 68 | 14 |
| Methylprednisolone | Methylprednisolone | 68 | 57 |
| Sildenafil Citrate | Sildenafil Citrate | 66 | 16 |
| Sucralfate | Sucralfate | 63 | 32 |
| Allopurinol | Allopurinol | 62 | 21 |
| Alprazolam | Alprazolam | 62 | 20 |
| Dexamethasone | Dexamethasone | 61 | 24 |
| Breyna | Budesonide/Formoterol Fumarate | 59 | 22 |
| Atenolol | Atenolol | 57 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 19 |
| Cefuroxime | Cefuroxime Axetil | 55 | 41 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 55 | 25 |
| Latanoprost | Latanoprost | 54 | 18 |
| Mirtazapine | Mirtazapine | 54 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 51 | 22 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | 19 |
| Ibuprofen | Ibuprofen | 49 | 25 |
| Methotrexate | Methotrexate Sodium | 48 | 11 |
| Naproxen | Naproxen | 47 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 16 |
| Hydrocortisone | Hydrocortisone | 45 | 19 |
| Nifedipine Er | Nifedipine | 45 | 16 |
| Mupirocin | Mupirocin | 41 | 24 |
| Spironolactone | Spironolactone | 41 | 17 |
| Cilostazol | Cilostazol | 40 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Bumetanide | Bumetanide | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 17 |
| Clonidine Hcl | Clonidine Hcl | 35 | 13 |
| Levofloxacin | Levofloxacin | 34 | 28 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 19 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 14 |
| Pentoxifylline | Pentoxifylline | 30 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 11 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 26 | 11 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 25 | 14 |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Baclofen | Baclofen | 23 | 11 |
| Tadalafil | Tadalafil | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | 15 |
| Valsartan | Valsartan | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Ciclopirox | Ciclopirox | 20 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | 13 |
| Primidone | Primidone | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Benzonatate | Benzonatate | 14 | 13 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $50.22 · 3 records | AstraZeneca Pharmaceuticals LP | FARXIGA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error